PPARD and Alzheimer disease: Thus far, only a single study has addressed the effects of PPARδ activation in a mouse model of AD, showing that 1-month treatment of 5XFAD mice with PPARδ agonist GW0742 led to reduction in brain Aβ burden, reduced astrocytic activation and increased expression of Aβ-degrading enzymes [18].